Tirzepatide side effects are overwhelmingly gastrointestinal: nausea, diarrhea, vomiting and constipation, worst during dose escalation. Less common risks include pancreatitis and gallbladder disease, and a boxed warning covers thyroid C-cell tumors. Compounded tirzepatide at Telos Rx is prescribed only after provider review.
One Molecule, Two Brand Names, One Safety Profile
Tirzepatide is a dual GIP and GLP-1 receptor agonist from Eli Lilly, injected subcutaneously once weekly. Mounjaro and Zepbound contain the same active molecule. Mounjaro is approved for glycemic control in type 2 diabetes; Zepbound for chronic weight management in adults with obesity or overweight plus a weight-related condition, and since December 2024 for moderate to severe obstructive sleep apnea.
So "mounjaro side effects", "side effects mounjaro" and "zepbound side effects" describe one compound, covered in Is Mounjaro tirzepatide? and What is tirzepatide? Every figure below comes from the FDA-approved brand labels or the phase 3 trials.
Gastrointestinal Effects Dominate the Data
In two pooled placebo-controlled trials covering 2,519 adults treated up to 72 weeks, gastrointestinal reactions occurred in 56 percent of patients at each dose studied, against 30 percent on placebo.
Scale matters as much as the list. Most events were mild to moderate, and the label states the majority occurred during dose escalation and decreased over time. Discontinuation specifically for them was 1.9, 3.3 and 4.3 percent by dose, against 0.5 percent on placebo.
Why the Titration Schedule Exists
The label starts at 2.5 mg weekly for four weeks, calls that a starting rather than maintenance dose, then permits 2.5 mg increases no sooner than every four weeks to a maximum of 15 mg. The stated reason is to reduce gastrointestinal reactions, and with a half-life near five days, a dose that does not agree with you is not gone by morning.
None of that is guidance to act on. The prescribing provider sets the schedule, and some people are evaluated for lower-dose approaches such as microdosed tirzepatide, detailed in the dosage schedule guide.
Common, Less Common, and Seek Care Now
| Category | Effect | What the label or trials reported |
|---|---|---|
| Common | Nausea | 25 to 29 percent vs 8 percent placebo |
| Common | Diarrhea | 19 to 23 percent vs 8 percent |
| Common | Constipation | 11 to 17 percent vs 5 percent |
| Common | Vomiting | 8 to 13 percent vs 2 percent |
| Common | Injection site reactions, fatigue, hair loss | 4 to 8 percent vs 1 to 3 percent |
| Less common | Acute gallbladder disease | Cholecystitis 0.7 vs 0.2 percent; gallstones 1.1 vs 1 |
| Less common | Acute pancreatitis | 0.2 percent adjudication-confirmed, the same rate as placebo |
| Less common | Severe hypersensitivity | 0.1 percent vs none; anaphylaxis postmarketing |
| Less common | Hypoglycemia | Rare alone; 9.9 to 19 percent with insulin or a sulfonylurea |
| Seek care now | Severe abdominal pain, may radiate to the back | Possible pancreatitis; label directs stopping |
| Seek care now | Neck lump, trouble swallowing, hoarseness | Boxed-warning thyroid symptoms |
| Seek care now | Swelling of face, lips or throat | Serious hypersensitivity |
| Seek care now | Right upper abdominal pain with fever, or jaundice | Possible gallbladder disease |
| Seek care now | Vomiting or diarrhea you cannot stay ahead of | Dehydration; kidney injury reported |
If you want a licensed provider to weigh this list against your own history, that starts with a written intake.
See tirzepatide at Telos RxThe Boxed Warning: Thyroid C-Cell Tumors
In rats, tirzepatide caused dose-dependent and duration-dependent thyroid C-cell tumors in a two-year study at clinically relevant exposures. Whether that translates to humans is not known, and the label says so plainly, adding that routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection.
What follows is firm regardless: tirzepatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2. That is a hard exclusion, not a caution. See Does tirzepatide cause cancer?
Pancreatitis, Gallbladder Disease and Kidney Risk
Acute pancreatitis, including necrotizing forms, has been observed with this drug class and with tirzepatide. In the pooled weight-reduction trials it was adjudication-confirmed in 0.2 percent of treated patients, the same rate as placebo. Gallbladder events did run above placebo, and the label ties them to weight reduction itself.
Severe vomiting or diarrhea can dehydrate enough to injure the kidneys, and acute kidney injury has been reported, in 0.5 percent versus 0.2 percent on placebo. Pulmonary aspiration during anesthesia or deep sedation has also been reported, so tell any surgical team.
Hypoglycemia Is a Combination Risk, Not a Standalone One
Tirzepatide stimulates insulin release in a glucose-dependent way, so alone it rarely drives blood sugar down dangerously. In the 40-week monotherapy trial, glucose below 54 mg/dL was reported in none of the tirzepatide groups versus 1 percent on placebo.
Combinations change that. Added to basal insulin, readings below 54 mg/dL reached 16, 19 and 14 percent by dose against 13 percent on placebo. With a sulfonylurea, rates were 13.8, 9.9 and 12.8 percent, severe in 0.5, 0 and 0.6 percent. On a metformin background in SURPASS-2, they were 0.2 to 1.7 percent. The label response is to consider lowering the insulin or secretagogue dose.
Mounjaro Side Effects in Women and in Men: Correcting the Premise
"Mounjaro side effects in women" and "mounjaro side effects in men" are rising searches built on a premise the evidence only partly supports. Both sexes were studied, and the labels set out one side-effect profile rather than separate ones by sex. The pooled weight-reduction population was 37 percent male; the SURPASS-4 diabetes trial was 63 percent men.
Two genuine sex-linked findings do exist. Because tirzepatide delays gastric emptying, it can reduce the effectiveness of oral hormonal contraceptives; the label advises switching to a non-oral method or adding a barrier method for four weeks after starting and after each dose increase. And the Zepbound label does break one adverse reaction out by sex: hair loss, reported in 7.1 percent of female patients versus 0.5 percent of male patients, against 1.3 percent and 0 percent on placebo. Beyond those two, reported differences track dose and escalation speed more than sex.
Pregnancy
Tirzepatide is not for use in pregnancy. The label is direct: weight loss offers no benefit to a pregnant patient and may cause fetal harm, and the drug should be stopped when pregnancy is recognized. Animal studies showed fetal growth reductions.
Who Was Excluded From the Trials
Safety data describe the people who were studied. SURMOUNT-1, the 72-week trial of 2,539 adults, excluded diabetes, prior pancreatitis, a personal or family history of medullary thyroid carcinoma or MEN 2, severe or unstable psychiatric illness, and any lifetime suicide attempt.
The labels add that pediatric safety for weight management is not established, and that use in severe gastroparesis or alongside another GLP-1 receptor agonist is not recommended. Excluded does not mean harmed. It means unmeasured.
When to Contact a Provider
The third block of the table is the short list for prompt medical attention. Below that, the rule is simple: anything that stops you eating or drinking normally for more than a day is worth reporting rather than waiting out. See how to manage GLP-1 side effects and the research on managing them.
Three effects have their own evidence picture: hair loss, 4 to 5 percent versus 1 percent on placebo, fatigue, 5 to 7 versus 3 percent, and anxiety.
Compounded Tirzepatide and Provider Review
Compounded tirzepatide is not FDA-approved. It is prepared by licensed US compounding pharmacies under federal compounding regulations against a prescription for an individual patient, and has not been through the FDA's review of safety and effectiveness. The brand prescribing information underpins everything above.
Telos Rx is an online-first, asynchronous, LegitScript-certified service. A written intake covers health history, thyroid and pancreatic history, pregnancy status and current medications. A licensed provider reviews it and responds in writing, often within hours, without a scheduled appointment. Approval is subject to evaluation by a licensed provider and is not guaranteed.
As of publication, the Telos Rx tirzepatide page lists pricing as low as $139 per month, flat as a provider titrates the dose, with free 48-hour shipping if approved and FSA/HSA accepted. See also getting tirzepatide online safely and the cost guide.
Frequently Asked Questions
What are the most common tirzepatide side effects?
Gastrointestinal effects, by a wide margin. In pooled placebo-controlled trials, nausea was reported in 25 to 29 percent of treated patients versus 8 percent on placebo, diarrhea in 19 to 23 percent, constipation in 11 to 17 percent and vomiting in 8 to 13 percent, mostly during dose escalation.
How long does tirzepatide diarrhea last?
The labels give no fixed duration, but state that the majority of nausea, vomiting and diarrhea occurred during dose escalation and decreased with continued treatment. Because the half-life is about five days, effects do not resolve within hours. Diarrhea severe enough to dehydrate should be reported to a provider.
Are Mounjaro side effects different for men and women?
Largely no. The labels set out one side-effect profile rather than separate ones by sex, and both sexes were studied: the pooled weight-reduction population was 37 percent male, and the SURPASS-4 diabetes trial was 63 percent men. Two exceptions are documented. Tirzepatide can reduce the effectiveness of oral hormonal contraceptives, and the Zepbound label reports hair loss in 7.1 percent of female versus 0.5 percent of male patients.
What is the tirzepatide boxed warning?
In rats, tirzepatide caused dose-dependent and duration-dependent thyroid C-cell tumors at clinically relevant exposures. Whether it does so in humans is unknown, because the relevance of the rodent finding has not been determined. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2.
Does tirzepatide cause low blood sugar?
Rarely on its own, because it works in a glucose-dependent way. In the monotherapy trial, glucose below 54 mg/dL was reported in none of the tirzepatide groups versus 1 percent on placebo. Risk rises in combination with insulin or a sulfonylurea, and the label directs prescribers to consider reducing those doses.
When should I contact a provider about a side effect?
Promptly for severe or persistent abdominal pain, a neck lump or persistent hoarseness, swelling of the face or throat, yellowing of the skin or eyes, or vomiting and diarrhea you cannot stay ahead of. Below that, report anything that stops you eating or drinking normally for more than a day.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Want a licensed provider to weigh this against your own history? Start on the tirzepatide product page, then complete the written intake: start an online visit. Approval is not guaranteed.